CONMED Corp (CNMD) shareholders
Close on Nov 17, 2026Market cap $1.44BP/E 20.0Yield 1.24%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,679,441 | 15.10% | 13G (passive) amendment | Jun 30, 2025 |
| EARNEST Partners, LLC | 2,784,300 | 9.00% | 13G (passive) amendment | Sep 30, 2024 |
| Vanguard Portfolio Management | 2,120,886 | 6.87% | 13G (passive) | Mar 31, 2026 |
| Fuller & Thaler Asset Management, Inc. | 1,740,630 | 5.63% | 13G (passive) | Jun 30, 2025 |
| Vanguard Capital Management | 1,619,070 | 5.25% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CNMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,820,739 | 16.18% | $157.78M | −4,434 | 0.00% |
| Earnest Partners LLC | 2,505,295 | 8.41% | $82.00M | −64,358 | 0.30% |
| Vanguard Portfolio Management LLC | 2,188,761 | 7.34% | $71.64M | +112,344 | 0.00% |
| Fuller & Thaler Asset Management, Inc. | 1,579,917 | 5.30% | $51.71M | −61,849 | 0.14% |
| State Street Corp | 1,417,468 | 4.76% | $46.39M | +33,450 | 0.00% |
| Vanguard Capital Management LLC | 1,355,728 | 4.55% | $44.37M | −28,314 | 0.00% |
| Bank Of America Corp /De/ | 1,341,409 | 4.50% | $43.90M | −61,211 | 0.00% |
| Dimensional Fund Advisors LP | 1,317,370 | 4.42% | $43.12M | −75,550 | 0.01% |
| Sei Investments Co | 988,151 | 3.32% | $32.34M | −16,564 | 0.03% |
| Invenomic Capital Management LP | 842,162 | 2.83% | $27.56M | −92,439 | 1.65% |
| Capital Research Global Investors | 823,636 | 2.76% | $26.96M | −101,812 | 0.00% |
| Geode Capital Management, LLC | 790,138 | 2.65% | $25.87M | +47,531 | 0.00% |
| Two Sigma Investments, LP | 728,976 | 2.45% | $23.86M | −53,564 | 0.02% |
| Allspring Global Investments Holdings, LLC | 618,447 | 2.08% | $20.26M | +35,714 | 0.03% |
| Cooke & Bieler LP | 573,498 | 1.92% | $18.77M | −414,285 | 0.22% |
| Paradigm Capital Management Inc/Ny | 538,245 | 1.81% | $17.62M | New | 0.48% |
| Arrowstreet Capital, Limited Partnership | 476,885 | 1.60% | $15.61M | +57,793 | 0.01% |
| Charles Schwab Investment Management Inc | 471,022 | 1.58% | $15.42M | −7,581 | 0.00% |
| Silvercrest Asset Management Group LLC | 441,361 | 1.48% | $14.45M | −207,216 | 0.09% |
| Goldman Sachs Group Inc | 436,830 | 1.47% | $14.30M | −39,818 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 246 | 34M | 100.0% | 44 / 84 | 82 / 30 | 3M | 3M |
| Q1 2026 | 236 | 34M | 100.0% | 32 / 98 | 74 / 57 | 8M | 6M |
| Q4 2025 | 266 | 36M | 100.0% | 47 / 100 | 94 / 51 | 7M | 5M |
| Q3 2025 | 273 | 35M | 100.0% | 45 / 96 | 99 / 47 | 4M | 5M |
| Q2 2025 | 277 | 35M | 100.0% | 45 / 97 | 95 / 45 | 3M | 3M |
| Q1 2025 | 280 | 36M | 100.0% | 44 / 99 | 96 / 40 | 3M | 3M |
| Q4 2024 | 280 | 36M | 100.0% | 40 / 97 | 98 / 44 | 4M | 2M |
| Q3 2024 | 290 | 34M | 100.0% | 41 / 95 | 110 / 39 | 7M | 4M |
| Q2 2024 | 290 | 36M | 100.0% | 37 / 111 | 108 / 44 | 4M | 5M |
| Q1 2024 | 298 | 37M | 100.0% | 53 / 108 | 106 / 60 | 6M | 6M |
| Q4 2023 | 306 | 38M | 100.0% | 55 / 128 | 90 / 21 | 3M | 1M |
| Q3 2023 | 275 | 36M | 100.0% | 54 / 97 | 90 / 41 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
271 funds held CNMD in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CNMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,814,383 | 6.09% | $59.38M | 0.05% | Jun 30, 2026 |
| Undiscovered Managers Behavioral Value Fund | 1,319,068 | 4.43% | $43.17M | 0.48% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 958,140 | 3.21% | $31.36M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 806,518 | 2.71% | $26.40M | 0.03% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 801,295 | 2.69% | $26.23M | 0.03% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 689,876 | 2.31% | $22.58M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 437,417 | 1.47% | $14.32M | 0.02% | Jun 30, 2026 |
| Allspring Special Small Cap Value Fund | 434,820 | 1.46% | $14.23M | 0.48% | Jun 30, 2026 |
| Harbor Small Cap Value Fund | 386,410 | 1.30% | $17.89M | 0.71% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 366,995 | 1.23% | $16.99M | 0.09% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 347,139 | 1.16% | $11.36M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 337,280 | 1.13% | $15.62M | 0.05% | Jul 31, 2026 |
| Invenomic Fund | 298,577 | 1.00% | $13.82M | 1.62% | Jul 31, 2026 |
| Small Cap Equity Portfolio | 287,401 | 0.96% | $13.31M | 1.28% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 279,591 | 0.94% | $9.15M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Hollie K. Foust | General Counsel & Corp Sec | 5,762 | 0.02% | Nov 6, 2026 |
| John E. Gallagher | Executive Vice President & CFO | 0 | – | Jul 17, 2026 |
| Kimberly Lockwood | Interim Corp Controller & PAO | 1,868 | 0.01% | Jun 3, 2026 |
| Pat Beyer | President & CEO | 10,807 | 0.04% | Apr 2, 2026 |
| Brent Lalomia | Executive VP RA, QA | 1,066 | 0.00% | Mar 18, 2026 |
| Matthew Schabacker | VP GM Advanced Surgical | 0 | – | Mar 18, 2026 |
| Peter K. Shagory | EVP, STRAT & CORP DEVT | 3,897 | 0.01% | Mar 18, 2026 |
| John D. Ferrell | Executive Vice President - HR | 2,402 | 0.01% | Mar 18, 2026 |
| Johonna Marie Pelletier | Treasurer and VP, Tax | 4,634 | 0.02% | Mar 4, 2026 |
| Andrew James Moller | VP Corporate Controller | 0 | – | Mar 4, 2026 |
| Richard Glaze | Chief Information Officer | 0 | – | Nov 24, 2025 |
| Todd W. Garner | Executive Vice President & CFO | 1,836 | 0.01% | Nov 7, 2025 |
| Stephan Epinette | VP GM International | 15,510 | 0.05% | May 15, 2025 |
| Edward A. Clifford | VP Global Manufacturing | 500 | 0.00% | Mar 5, 2025 |
| Kim Kelderman | Director | 500 | 0.00% | Sep 10, 2026 |
| Celine Christine Martin | Director | 0 | – | Jul 2, 2026 |
| Jeffrey B. Mirviss | Director | 0 | – | Jul 2, 2026 |
| Mark Kaye | Director | 820 | 0.00% | Jun 3, 2026 |
| David M. Bronson | Director | 17,909 | 0.06% | Jun 3, 2026 |
| Charles Farkas | Director | 15,527 | 0.05% | Jun 3, 2026 |
| Barbara J. Schwarzentraub | Director | 6,454 | 0.02% | Jun 3, 2026 |
| LaVerne H. Council | Director | 4,716 | 0.02% | Jun 3, 2026 |
| Brian Concannon | Director | 10,116 | 0.03% | Jun 4, 2025 |
| Martha Goldberg Aronson | Director | 14,391 | 0.05% | Jun 4, 2025 |
| John L. Workman | Director | 20,891 | 0.07% | May 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hollie K. Foust General Counsel & Corp Sec | Nov 4, 2026 | Tax withholding | −1,124 | $53.66 | $60.31K | 5,762 |
| Hollie K. Foust General Counsel & Corp Sec | Nov 4, 2026 | Option exercise | +4,000 | – | – | 6,886 |
| Kim Kelderman Director | Sep 8, 2026 | Option exercise | +500 | – | – | 500 |
| Mark Kaye Director | Jun 2, 2026 | Option exercise | +668 | – | – | 820 |
| David M. Bronson Director | Jun 2, 2026 | Option exercise | +668 | – | – | 17,909 |
| Barbara J. Schwarzentraub Director | Jun 2, 2026 | Option exercise | +668 | – | – | 5,012 |
| LaVerne H. Council Director | Jun 2, 2026 | Option exercise | +668 | – | – | 4,716 |
| Charles Farkas Director | Jun 2, 2026 | Option exercise | +668 | – | – | 15,527 |
| Brent Lalomia Executive VP RA, QA | Mar 6, 2026 | Option exercise | +75 | – | – | 941 |
| Brent Lalomia Executive VP RA, QA | Mar 6, 2026 | Tax withholding | −26 | $39.90 | $1.04K | 915 |
| Mark Kaye Director | Feb 24, 2026 | Option exercise | +152 | – | – | 152 |
| Brent Lalomia Executive VP RA, QA | Dec 31, 2025 | Other | +31.63 | $40.60 | $1.28K | 125 |
| Richard Glaze Chief Information Officer | Nov 21, 2025 | Sale(10b5-1 plan) | −257 | $41.21 | $10.59K | 0 |
| Richard Glaze Chief Information Officer | Nov 20, 2025 | Option exercise | +375 | – | – | 375 |
| Richard Glaze Chief Information Officer | Nov 20, 2025 | Tax withholding | −118 | $40.63 | $4.79K | 257 |
| Todd W. Garner Executive Vice President & CFO | Nov 6, 2025 | Sale(10b5-1 plan) | −3,500 | $43.00 | $150.50K | 1,836 |
| Hollie K. Foust General Counsel & Corp Sec | Nov 4, 2025 | Tax withholding | −1,114 | $45.71 | $50.92K | 2,886 |
| Hollie K. Foust General Counsel & Corp Sec | Nov 4, 2025 | Option exercise | +4,000 | – | – | 4,000 |
| Todd W. Garner Executive Vice President & CFO | Oct 31, 2025 | Tax withholding | −2,164 | $44.00 | $95.22K | 5,336 |
| Todd W. Garner Executive Vice President & CFO | Oct 31, 2025 | Option exercise | +7,500 | – | – | 7,500 |
| Charles Farkas Director | Sep 12, 2025 | Sale | −897 | $53.51 | $48.00K | 14,859 |
| Charles Farkas Director | Sep 12, 2025 | Sale | −1,103 | $53.54 | $59.05K | 15,756 |
| Todd W. Garner Executive Vice President & CFO | Aug 7, 2025 | Sale | −598 | $52.45 | $31.37K | 0 |
| LaVerne H. Council Director | Jun 3, 2025 | Option exercise | +479 | – | – | 4,048 |
| Martha Goldberg Aronson Director | Jun 3, 2025 | Option exercise | +479 | – | – | 12,391 |
| David M. Bronson Director | Jun 3, 2025 | Option exercise | +479 | – | – | 17,241 |
| Charles Farkas Director | Jun 3, 2025 | Option exercise | +479 | – | – | 16,859 |
| Brian Concannon Director | Jun 3, 2025 | Option exercise | +479 | – | – | 10,116 |
| Barbara J. Schwarzentraub Director | Jun 3, 2025 | Option exercise | +479 | – | – | 4,344 |
| Charles Farkas Director | May 29, 2025 | Tax withholding | −966 | $57.69 | $55.73K | 16,380 |
| Charles Farkas Director | May 29, 2025 | Option exercise | +1,000 | $55.70 | $55.70K | 17,346 |
| John L. Workman Director | May 20, 2025 | Option exercise | +479 | $59.84 | $28.66K | 20,891 |
| Charles Farkas Director | May 5, 2025 | Sale | −4,000 | $56.94 | $227.76K | 16,346 |
| Todd W. Garner Executive Vice President & CFO | Mar 31, 2025 | Award | +371 | $57.37 | $21.28K | 598 |
| Peter K. Shagory EVP, STRAT & CORP DEVT | Mar 14, 2025 | Tax withholding | −4,316 | $58.83 | $253.91K | 3,897 |
| Peter K. Shagory EVP, STRAT & CORP DEVT | Mar 14, 2025 | Option exercise | +4,500 | $55.42 | $249.39K | 8,213 |
| Brent Lalomia Vice President QA and RA | Mar 7, 2025 | Option exercise | +75 | – | – | 1,032 |
| Brent Lalomia Vice President QA and RA | Mar 7, 2025 | Tax withholding | −26 | $62.74 | $1.63K | 1,006 |
| Richard Glaze Chief Information Officer | Feb 11, 2025 | Sale | −257 | $65.35 | $16.79K | 0 |
| Brent Lalomia Executive VP RA, QA | Dec 31, 2024 | Other | +22.99 | $68.44 | $1.57K | 94 |
| Richard Glaze Chief Information Officer | Nov 20, 2024 | Tax withholding | −118 | $70.69 | $8.34K | 257 |
| Richard Glaze Chief Information Officer | Nov 20, 2024 | Option exercise | +375 | – | – | 375 |
| Curt R. Hartman President and CEO, Director | Nov 7, 2024 | Tax withholding | −24,303 | $74.76 | $1.82M | 9,996 |
| Curt R. Hartman President and CEO, Director | Nov 7, 2024 | Option exercise | +30,000 | $51.30 | $1.54M | 34,299 |
| Charles Farkas Director | Sep 5, 2024 | Option exercise | +1,000 | $39.64 | $39.64K | 20,880 |
| Charles Farkas Director | Sep 5, 2024 | Tax withholding | −534 | $74.31 | $39.68K | 20,346 |
| Edward A. Clifford VP Global Manufacturing | Aug 1, 2024 | Option exercise | +500 | – | – | 500 |
| Edward A. Clifford VP Global Manufacturing | Aug 1, 2024 | Tax withholding | −122 | $65.34 | $7.97K | 378 |
| Stanley W. Peters III President AS and AET | Jun 14, 2024 | Option exercise | +4,000 | $41.93 | $167.72K | 4,063 |
| Stanley W. Peters III President AS and AET | Jun 14, 2024 | Sale | −4,000 | $71.82 | $287.28K | 63 |
| Brian Concannon Director | May 31, 2024 | Option exercise | +302 | – | – | 9,637 |
| Barbara J. Schwarzentraub Director | May 31, 2024 | Option exercise | +302 | – | – | 3,865 |
| Charles Farkas Director | May 31, 2024 | Option exercise | +302 | – | – | 19,880 |
| David M. Bronson Director | May 31, 2024 | Option exercise | +302 | – | – | 16,762 |
| Jerome J. Lande Director | May 31, 2024 | Option exercise | +302 | – | – | 3,856 |
| John L. Workman Director | May 31, 2024 | Option exercise | +302 | – | – | 20,412 |
| Martha Goldberg Aronson Director | May 31, 2024 | Option exercise | +302 | – | – | 11,912 |
| LaVerne H. Council Director | May 31, 2024 | Option exercise | +302 | – | – | 3,569 |
| David M. Bronson Director | May 13, 2024 | Buy | +1,350 | $72.09 | $97.32K | 16,460 |
| Barbara J. Schwarzentraub Director | May 8, 2024 | Buy | +1,442 | $69.26 | $99.87K | 1,442 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Conmed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,268 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Glaze Officer | Nov 21, 2025 | 257 | $10.59K | Nov 21, 2025 | Restricted Stock Vesting |
| Todd W. Garner Officer | Nov 6, 2025 | 3,500 | $150.50K | Nov 6, 2025 | Restricted Stock Vesting |
| Charles Farkas Director | Sep 12, 2025 | 2,000 | $107.05K | Sep 12, 2025 | Restricted Stock Vesting |
| Todd W. Garner Officer | Aug 7, 2025 | 598 | $31.37K | Aug 7, 2025 | ESPP Purchase |
| Charles Farkas Director | May 5, 2025 | 4,000 | $227.77K | May 5, 2025 | Restricted Stock Vesting |
| Curt R. Hartman Former Officer | Feb 14, 2025 | 2,905 | $188.51K | Feb 14, 2025 | Stock Appreciation Rights |
| Curt R. Hartman Former Officer | Feb 13, 2025 | 4,986 | $313.87K | Feb 13, 2025 | Stock Appreciation Rights |
| Richard Glaze Officer | Feb 11, 2025 | 257 | $16.80K | Feb 11, 2025 | Restricted Stock Vesting |
| Curt R. Hartman Officer, Director | Nov 8, 2024 | 2,849 | $213.22K | Nov 8, 2024 | Stock Appreciation Rights |
| Stanley W. Peters III Officer | Aug 27, 2024 | 2,171 | $157.18K | Aug 27, 2024 | Stock Appreciation Rights |
| Stanley W. Peters III Officer | Jun 14, 2024 | 4,000 | $287.28K | Jun 14, 2024 | Option Granted - 03/01/2017 |
| Stanley W. Peters III Officer | Dec 4, 2023 | 2,300 | $252.83K | Dec 4, 2023 | Option Granted 03/01/2017 |
| Stanley W. Peters III Officer | Nov 7, 2023 | 1,200 | $122.87K | Nov 7, 2023 | Option Granted - 03/01/2017 |
| Stanley W. Peters III Officer | Sep 13, 2023 | 2,000 | $214.63K | Sep 13, 2023 | Option Granted - 03/01/2017 |
| Todd W. Garner Officer | Aug 16, 2023 | 1,355 | $151.76K | Aug 16, 2023 | ESPP Purchase |
Congress trades
2 trades in Conmed reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Nicholas Van Taylor TX03 · spouse | Sold | Mar 25, 2019 | $1K–15K | Apr 15, 2019 |
| Nicholas Van Taylor TX03 · spouse | Bought | Feb 15, 2019 | $1K–15K | Mar 14, 2019 |
See a number that looks wrong?